Investing in a $1.1 Trillion Sector Wrecked by COVID

We all seem to throw the word “crisis” around a little too frequently these days. 

Perhaps that’s just one of the natural consequences of being locked down for more than a year. 

So when I ask you what the worst part of it has been so far, I’m sure I would be flooded with a wide array of answers. 

For some it’s the masks and being locked inside for months on end. 

Others would claim it was the complete and utter devastation of the global economy. 

Whatever your own answer may be, it’s safe to say that the COVID-19 crisis has no end in sight. 

However, the doom-and-gloom headlines have shifted over the last few months.  

By last July, there were four main variants of SARS-CoV-2 burning their way through the world’s population. 

Today, the media are hyper-focused on the Mu variant — the most recent COVID variant to be listed as a threat by the World Health Organization. 

Sometimes, the chaos this pandemic has levied on us can seem unbearable. 

Well, let me show you how to take back control. 

There’s an old Chinese proverb that says, “A crisis is an opportunity riding the dangerous wind.”

You’ve heard it before, haven’t you?

It’s one that the veteran members of our investment community here have heard my colleagues and me say time and again. 

It’s the same sentiment that should immediately spring to mind whenever this pandemic starts to overwhelm you.

Say it again with me: “Crisis breeds opportunity.”

Look, you don’t need me to tell you that the COVID pandemic has bred unprecedented opportunities. 

Nowhere else has this become more evident than the $1.1 trillion biotech sector. 

I doubt many investors understand the level of crisis that erupted in biotech stocks during the pandemic. 

And it all started with one massively underreported statement from the U.S. Food and Drug Administration (FDA). 

On March 18, 2020, the former commissioner of Food and Drugs at the FDA announced that all domestic inspections were temporarily halted except those that were deemed “mission-critical” at the time. 

What did this actually mean?

For the next 13 months, the FDA effectively stopped its site visits for thousands of facilities, meaning if you had a new drug almost ready to market, your approval would’ve been postponed unless it fell within the strict criteria of being mission-critical.  

Although you may not have heard this story, its effect rippled profoundly throughout the biotech sector. 

OK, so how bad are we talking?

For new drugs being developed, the FDA’s inability to inspect facilities and manufacturing plants (which it must do in person) has exacted a punishing toll on the sector. 

So the FDA did the only thing it could: delay.

Soon that flood of approvals will be unleashed on the market as the FDA frantically tries to clear its massive inspection backlog.

You see, the FDA announced a detailed plan last May to get back on track, even going so far as to lay out a road map for inspectional oversight. 

And that, dear reader, is one helluva opportunity for individual investors like us.

Imagine having a head start over Wall Street, knowing exactly which biotech stocks are about to receive their long-awaited approval. 

Stay tuned, because over the next few weeks I’m going to show you how my readers have closed winner after winner by taking advantage of this enormous bottleneck.

And the best part is we’re still in the early stages of this biotech boom.

Until next time,

Keith Kohl

Check us out on YouTube!

A true insider in the technology and energy markets, Keith’s research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing’s Energy Investor and Technology and Opportunity.

For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology.

Keith’s keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith’s Topline Trader advisory newsletter.